Bernstein Keeps Their Buy Rating on Elevance Health (ELV)

Bernstein analyst Lance Wilkes maintained a Buy rating on Elevance Health today and set a price target of $420.00. The company’s shares closed yesterday at $349.49.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Wilkes covers the Healthcare sector, focusing on stocks such as UnitedHealth, HCA Healthcare, and Elevance Health. According to TipRanks, Wilkes has an average return of -1.1% and a 47.73% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Elevance Health with a $376.24 average price target, which is a 7.65% upside from current levels. In a report released on October 14, Truist Financial also maintained a Buy rating on the stock with a $400.00 price target.

The company has a one-year high of $458.75 and a one-year low of $273.71. Currently, Elevance Health has an average volume of 2.42M.

Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ELV in relation to earlier this year. Most recently, in August 2025, Susan Devore, a Director at ELV bought 1,200.00 shares for a total of $374,580.00.